The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens
- 26 April 2012
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 69 (6) , 1591-1599
Abstract
We are trying to identify predictive factors of high risk of toxicity by analyzing candidate genes in the irinotecan pathways in order to identify useful tools to improve mCRC patient management under real practice conditions.Keywords
This publication has 28 references indexed in Scilit:
- A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancerBritish Journal of Cancer, 2011
- UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapyBritish Journal of Cancer, 2010
- Dose-dependent association between UGT1A1∗28 polymorphism and irinotecan-induced diarrhoea: A meta-analysisEuropean Journal of Cancer, 2010
- Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2010
- The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimensJournal of Cancer Research and Clinical Oncology, 2009
- Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and PharmacokineticsJournal of Clinical Oncology, 2009
- Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and IrinotecanJournal of Clinical Oncology, 2009
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyJournal of Clinical Oncology, 2008
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Journal of Clinical Oncology, 2007